GB0624879D0 - Treatment of pervasive development disorders - Google Patents

Treatment of pervasive development disorders

Info

Publication number
GB0624879D0
GB0624879D0 GBGB0624879.3A GB0624879A GB0624879D0 GB 0624879 D0 GB0624879 D0 GB 0624879D0 GB 0624879 A GB0624879 A GB 0624879A GB 0624879 D0 GB0624879 D0 GB 0624879D0
Authority
GB
United Kingdom
Prior art keywords
treatment
protein
source
development disorders
pervasive development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0624879.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shs Int Ltd
SHS International Ltd
Original Assignee
Shs Int Ltd
SHS International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shs Int Ltd, SHS International Ltd filed Critical Shs Int Ltd
Priority to GBGB0624879.3A priority Critical patent/GB0624879D0/en
Publication of GB0624879D0 publication Critical patent/GB0624879D0/en
Priority to PCT/GB2007/004815 priority patent/WO2008071991A1/en
Priority to PL07858785T priority patent/PL2091526T3/pl
Priority to DE602007014400T priority patent/DE602007014400D1/de
Priority to EP07858785A priority patent/EP2091526B1/en
Priority to CA002672738A priority patent/CA2672738A1/en
Priority to BRPI0720230A priority patent/BRPI0720230B8/pt
Priority to ZA200904240A priority patent/ZA200904240B/xx
Priority to JP2009540868A priority patent/JP2010513259A/ja
Priority to AT07858785T priority patent/ATE507827T1/de
Priority to RU2009126763/15A priority patent/RU2441652C2/ru
Priority to ES07858785T priority patent/ES2365469T3/es
Priority to MX2009006459A priority patent/MX2009006459A/es
Priority to AU2007331276A priority patent/AU2007331276A1/en
Priority to US12/483,580 priority patent/US20100055073A1/en
Priority to IL199340A priority patent/IL199340A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0624879.3A 2006-12-14 2006-12-14 Treatment of pervasive development disorders Ceased GB0624879D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0624879.3A GB0624879D0 (en) 2006-12-14 2006-12-14 Treatment of pervasive development disorders
AU2007331276A AU2007331276A1 (en) 2006-12-14 2007-12-14 Treatment of pervasive developmental disorders
BRPI0720230A BRPI0720230B8 (pt) 2006-12-14 2007-12-14 formulação nutricional oralmente administrável, uso da formulação, e, composição
JP2009540868A JP2010513259A (ja) 2006-12-14 2007-12-14 広汎性発達障害の治療
DE602007014400T DE602007014400D1 (de) 2006-12-14 2007-12-14 Behandlung pervasiver entwicklungsstörungen
EP07858785A EP2091526B1 (en) 2006-12-14 2007-12-14 Treatment of pervasive developmental disorders
CA002672738A CA2672738A1 (en) 2006-12-14 2007-12-14 Treatment of pervasive developmental disorders
PCT/GB2007/004815 WO2008071991A1 (en) 2006-12-14 2007-12-14 Treatment of pervasive developmental disorders
ZA200904240A ZA200904240B (en) 2006-12-14 2007-12-14 Treatment of pervasive development disorders
PL07858785T PL2091526T3 (pl) 2006-12-14 2007-12-14 Leczenie całościowych zaburzeń rozwojowych
AT07858785T ATE507827T1 (de) 2006-12-14 2007-12-14 Behandlung pervasiver entwicklungsstörungen
RU2009126763/15A RU2441652C2 (ru) 2006-12-14 2007-12-14 Лечение общих расстройств развития
ES07858785T ES2365469T3 (es) 2006-12-14 2007-12-14 Tratamiento de trastornos generalizados del desarrollo.
MX2009006459A MX2009006459A (es) 2006-12-14 2007-12-14 Tratamiento de trastornos pervasivos del desarrollo.
US12/483,580 US20100055073A1 (en) 2006-12-14 2009-06-12 Treatment of pervasive developmental disorders
IL199340A IL199340A0 (en) 2006-12-14 2009-06-14 Treatment of pervasive developmental disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0624879.3A GB0624879D0 (en) 2006-12-14 2006-12-14 Treatment of pervasive development disorders

Publications (1)

Publication Number Publication Date
GB0624879D0 true GB0624879D0 (en) 2007-01-24

Family

ID=37712065

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0624879.3A Ceased GB0624879D0 (en) 2006-12-14 2006-12-14 Treatment of pervasive development disorders

Country Status (16)

Country Link
US (1) US20100055073A1 (enExample)
EP (1) EP2091526B1 (enExample)
JP (1) JP2010513259A (enExample)
AT (1) ATE507827T1 (enExample)
AU (1) AU2007331276A1 (enExample)
BR (1) BRPI0720230B8 (enExample)
CA (1) CA2672738A1 (enExample)
DE (1) DE602007014400D1 (enExample)
ES (1) ES2365469T3 (enExample)
GB (1) GB0624879D0 (enExample)
IL (1) IL199340A0 (enExample)
MX (1) MX2009006459A (enExample)
PL (1) PL2091526T3 (enExample)
RU (1) RU2441652C2 (enExample)
WO (1) WO2008071991A1 (enExample)
ZA (1) ZA200904240B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
MX2013003636A (es) 2013-03-27 2014-09-29 Palsgaard Ind De Mexico S De R L De C V Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad.
WO2015002527A1 (en) * 2013-07-05 2015-01-08 N.V. Nutricia Amino acid composition for use in the treatment of a pdd
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
EP3630124A4 (en) * 2017-05-24 2021-02-24 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2022258873A1 (es) * 2021-06-09 2022-12-15 Hospital Sant Joan De Deu Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
SE510813C2 (sv) * 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
CN1255413C (zh) * 2001-06-14 2006-05-10 阿克佐诺贝尔公司 作为ampa受体正性调节剂的(吡啶并/噻吩并)－[f]－氧杂吖庚因－5－酮衍生物
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Also Published As

Publication number Publication date
MX2009006459A (es) 2009-11-23
ES2365469T3 (es) 2011-10-06
EP2091526B1 (en) 2011-05-04
AU2007331276A2 (en) 2011-03-31
ATE507827T1 (de) 2011-05-15
RU2441652C2 (ru) 2012-02-10
DE602007014400D1 (de) 2011-06-16
BRPI0720230B8 (pt) 2021-05-25
BRPI0720230A2 (pt) 2013-12-24
PL2091526T3 (pl) 2011-10-31
IL199340A0 (en) 2010-03-28
AU2007331276A1 (en) 2008-06-19
CA2672738A1 (en) 2008-06-19
BRPI0720230B1 (pt) 2020-12-15
WO2008071991A1 (en) 2008-06-19
RU2009126763A (ru) 2011-01-20
EP2091526A1 (en) 2009-08-26
US20100055073A1 (en) 2010-03-04
JP2010513259A (ja) 2010-04-30
ZA200904240B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
IL199340A0 (en) Treatment of pervasive developmental disorders
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
TW200637614A (en) Bendamustine pharmaceutical compositions
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
NZ709704A (en) Protein formulations and methods of making same
WO2008137758A3 (en) Amino acid lipids and uses thereof
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
RU2011101713A (ru) Фармацевтическая композиция
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
SI2185561T1 (sl) Derivati 1,2,3,4-tetrahidropirolo(1,2-alfa)pirazin-6-karboksamidov in 2,3,4,5-tetrahidropirolo(1,2-alfa)-diazepin-7-karboksamidov, njihova priprava in njihova terapevtska uporaba
AU2012382949A8 (en) Compositions and methods for treatment of neuropsychological deficits
UA104281C2 (ru) Противоопухолевые аналоги пептидов, способ их получения и фармацевтическая композиция на них основе

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)